Sue Decotiis, M.D., a triple board-certified physician in internal medicine, antiaging medicine, and obesity medicine, who leads a weight-loss practice in Scarsdale, NY
Possible side effects may include mild injection-site irritation, temporary headaches, or brief flushing
Spending on glucagonlike peptide1 receptor agonists, or GLP1s, in the United States increased over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to the Journal of the American Heart Association, Although these medications were initially developed to treat Type 2 diabetes, newer indications now include weight management
Every proposal has key staff and a Principal Investigator (PI) who must work at least 50% of their time at the company
Obesity-only indications face more insurance barriers